SPI-1005 (Ebselen) Status Update (April 2026) and it's all good news.
Sound Pharmaceuticals have developed the first treatment for menieres (and other inner conditions) this is an update from April 2026 for those that are unaware.
-Ask your doctor about it. Make a fuss. The more demand the faster the approval will be.
Pencil in maybe the end of 2026 or 2027 for US release and ROW thereafter. Certainly well before the end of the decade. Patience is key.
We live in amazing times, chances are this disease will be successfully controlled in just a few years.
Summary: SPI-1005 (Ebselen) Status Update (April 2026)
The Big News: SPI-1005 has successfully met its primary goals in Phase 3 clinical trials (STOPMD-3). It has officially been shown to successfully treat Meniere’s Disease by significantly improving low-frequency hearing and speech discrimination compared to a placebo.
Current Status:
FDA Breakthrough Status: Following the trial's success, the FDA granted SPI-1005 Breakthrough Therapy Designation, fast-tracking it as a potentially groundbreaking treatment.
Safety Trials: A final long-term safety study is currently active to support its use as a chronic or intermittent treatment. The trial patients need to take the medicine for a period of 12 months or more to assess safety (any side effects etc..).
Availability: While the medicine has proven successful in trials, it is not yet on pharmacy shelves. The safety study is expected to conclude in December 2026, which is the final step before the FDA can grant full approval for prescription use.
How it Works:
Unlike traditional treatments that only manage symptoms, SPI-1005 targets the underlying neuroinflammation in the inner ear.
By mimicking a natural enzyme (GPx), it protects the ear from damage and helps restore auditory and vestibular function.